Letrozole

Breast Cancer Treatment

Letrozole is primarily used to treat hormone receptor-positive breast cancer in postmenopausal women. It works by decreasing the amount of estrogen the body produces, which can slow or stop the growth of certain types of breast cancer cells that need estrogen to grow.

• Early Breast Cancer: It is used as an initial treatment after surgery or other primary therapies to reduce the risk of the cancer returning.
• Extended Treatment: It is often prescribed for women who have already completed five years of treatment with tamoxifen to further lower the risk of recurrence.
• Advanced or Metastatic Cancer: It is used as a first-line treatment for breast cancer that has spread within the breast or to other parts of the body. It may also be used if the cancer has worsened after treatment with other antiestrogen medications.

Other Uses

Healthcare providers may sometimes use letrozole for purposes not approved by the FDA, such as helping with ovulation in women who are experiencing infertility. This is considered an off-label use of the medication.

Mechanism of Action

Letrozole belongs to a class of medications known as aromatase inhibitors. It works by blocking an enzyme called aromatase, which the body uses to produce estrogen.

Lowering Estrogen Levels

In women who have gone through menopause, the ovaries no longer produce significant amounts of estrogen. Instead, the body creates estrogen by converting other hormones, called androgens, into estrogen using the aromatase enzyme. Letrozole interferes with this process, significantly reducing the total amount of estrogen circulating in the body.

Impact on Breast Cancer

Many types of breast cancer are hormone-sensitive, meaning they rely on estrogen to grow and spread. By lowering estrogen levels, letrozole helps to:

• Slow down the growth of existing tumors.
• Stop the spread of cancer cells to other parts of the body.
• Reduce the risk of cancer returning after surgery or other treatments.

Other Effects

Because letrozole lowers estrogen levels, it can also affect how the brain regulates reproductive hormones. In certain clinical situations, the drop in estrogen signals the pituitary gland to increase the production of follicle-stimulating hormone (FSH), which can stimulate the ovaries.

Common Side Effects

Many people taking letrozole experience mild to moderate side effects. These often include:

• Hot flashes and night sweats
• Joint, bone, or muscle pain
• Fatigue or unusual tiredness
• Headache
• Dizziness
• Nausea
• Swelling in the hands, feet, or ankles
• Weight gain
• Increased cholesterol levels
• Thinning hair
• Vaginal dryness or irritation

Serious Side Effects

While less common, some side effects require immediate medical attention. Contact a healthcare provider right away if you experience:

• Signs of a blood clot or stroke, such as sudden numbness, weakness on one side of the body, or difficulty speaking
• Chest pain or pressure
• Shortness of breath
• Blurred vision or other vision changes
• Signs of liver problems, such as yellowing of the eyes or skin (jaundice) or dark urine
• Severe allergic reactions, including rash, hives, or swelling of the face and throat

Long-Term Considerations

Letrozole can decrease bone mineral density, which may increase the risk of osteoporosis or bone fractures. Healthcare providers often monitor bone health during treatment. Additionally, letrozole is not for use during pregnancy as it can cause harm to an unborn baby.

Pregnancy and Fetal Risk

Letrozole is contraindicated in women who are or may become pregnant because it can cause significant harm to a developing fetus. Women of childbearing potential should use effective contraception during treatment and for a period after the final dose.

Bone Mineral Density

Because letrozole lowers estrogen levels, it can lead to a decrease in bone mineral density. This may increase the risk of osteoporosis and bone fractures. Monitoring of bone density is recommended for patients at risk.

Cholesterol Monitoring

Increases in total cholesterol have been observed in some patients. Healthcare providers may monitor blood cholesterol levels periodically during therapy.

Hepatic Impairment

Caution is recommended for patients with severe liver disease. The medication's clearance from the body may be affected, potentially requiring dosage adjustments.

Effects on Driving

Fatigue, dizziness, and sleepiness have been reported with letrozole use. It is advisable to avoid driving or using machinery until the individual's reaction to the drug is determined.

Pregnancy

Letrozole is not intended for use during pregnancy. It can cause significant harm to a developing fetus or lead to pregnancy loss. Before starting treatment, a pregnancy test is typically required for individuals who are able to become pregnant to confirm they are not pregnant.

Effective birth control should be used during treatment and for at least three weeks after the last dose. If you suspect you have become pregnant while taking this medication, contact your healthcare provider immediately to discuss the potential risks.

Breastfeeding

It is not known if letrozole passes into human breast milk. Because of the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment and for at least three weeks following the final dose.

Fertility

This medication may impair fertility in both males and females, which could impact the ability to have children in the future. Discuss any concerns regarding fertility with a healthcare professional before beginning treatment.

Available Forms

Letrozole is available in the following form for oral administration:

• Oral Tablet: A film-coated tablet taken by mouth.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) has approved letrozole for several specific uses in postmenopausal women with breast cancer. These indications include:

• Adjuvant treatment for hormone receptor-positive early breast cancer.
• Extended adjuvant treatment for early breast cancer in patients who have finished five years of tamoxifen therapy.
• First-line treatment for hormone receptor-positive or hormone receptor-unknown advanced or metastatic breast cancer.
• Treatment of advanced breast cancer in patients whose disease has progressed after antiestrogen therapy.

Safety Communications and Labeling

The FDA monitors the safety of letrozole through post-marketing surveillance. In 2020, the FDA identified a potential safety signal regarding tendon rupture associated with the use of aromatase inhibitors, including letrozole. This led to updates in the drug's labeling to reflect this risk.

There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) associated with letrozole. The medication is available by prescription only.

Weight Changes and Letrozole

Letrozole is an aromatase inhibitor used to treat certain types of breast cancer; it is not intended for use as a weight loss aid. Clinical data indicates that weight changes are a known side effect of the medication, but these changes typically involve weight increase rather than decrease.

Weight Gain vs. Weight Loss

• Weight Gain: Clinical trials have shown that weight increase is a common side effect for patients taking letrozole. This may be related to the drug's effect on estrogen levels, which can influence metabolism and body composition.
• Weight Loss: While weight loss is not a typical side effect of letrozole alone, it may occur in patients receiving combination therapies or those experiencing other side effects like nausea or loss of appetite.

Because letrozole is often taken for several years as part of long-term cancer therapy, managing weight through diet and exercise is often recommended by healthcare providers. If you experience significant or unexplained changes in your weight while taking this medication, you should consult your doctor to discuss management strategies and rule out other underlying causes.